This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event from December 12 - 16, 2021
Live In-Person Experience Delivered December 12 - 16 2021Marriott Marquis San Diego

Mitchell Ho, PhD
Senior Investigator, Laboratory of Molecular Biology at NIH NCI


Dr. Ho is Senior Investigator, Deputy Chief of the Laboratory of Molecular Biology, and Director of the Antibody Engineering Program at the National Cancer Institute, NIH. He is the Chair of the Department of Biochemistry for the FAES Graduate School at the NIH. He also serves as the Editor-in-Chief for Antibody Therapeutics (Oxford University Press).

Dr. Ho’s research has been focused on the development of new therapeutic paradigms for several difficult to treat cancers including liver cancer, rare cancers such as mesothelioma, and childhood cancers such as neuroblastoma. Dr. Ho has led a research team to develop an original and multidisciplinary research program that establishes a group of cell surface proteins called glypicans including GPC3 and GPC2 as a new family of cancer therapeutic targets and combines state-of-the-art antibody engineering with a strong preclinical and clinical evaluation pipeline.

Dr. Ho received his Ph.D. from the University of Illinois at Urbana-Champaign. He completed a postdoctoral fellowship with Ira Pastan at the NIH/NCI. He was elected to the Board of Directors for the Antibody Society and to the Board of Directors for the Foundation for Advanced Education in the Sciences (FAES). He received Asian & Pacific Islander American Organization (APAO) Scientific Achievement Award, NIH Deputy Director for Intramural Research (DDIR) Innovation Award, NIH Merit Award, NCI Director's Award and NCI Director’s Innovation Award.

Agenda Sessions

  • Chairman’s Remarks

  • Camel and Shark Single Domain Antibodies Targeting Cancer and Viral Antigens